BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Reexamination Status of Gevo, Inc. Patents: USPTO Orders Re-examination of Gevo "AFT" Patent 8,017,376 and Butamax Requests Reexamination of Gevo "GIFT" Patent 8,101,808


5/3/2012 12:17:46 PM

WILMINGTON, Del., May 3, 2012 -- Butamax™ Advanced Biofuels, LLC announced today that it is requesting that the United States Patent and Trademark Office (USPTO) reexamine the Gevo “GIFT” Patent No. 8,101,808. This patent has 156 claims that relate to recovery of alcohols from fermentation.

The Butamax request for reexamination cites critical references not reviewed by the USPTO prior to the patent being granted, including a reference related to a validity challenge by Brazilian researchers. Butamax believes these references show that the technology claimed in the ‘808 patent was well known at the time the patent was filed. Butamax expects an answer to the reexamination request in early August. Gevo filed suit against Butamax asserting this patent in January 2012, and trial in this case is set for July 2014.

This request follows a March 23rd USPTO decision where an order was issued granting Butamax’s request for reexamination of Gevo patent 8,017,376 (“the ‘376 patent”). Further, the USPTO issued an Office Action rejecting claims 1-8, 10-15 and 17-20 of the ‘376 patent as anticipated by a Butamax patent application (International Publication No. WO 2011/103300 A2). This means that these claims are subject to reexamination by the USPTO on at least the basis that they were previously described in an earlier Butamax patent application.

Based on USPTO statistics, it is likely to be some time before the reexamination proceedings are concluded. On average, reexamination takes about three years. Since patents remain in effect during the reexamination process, the infringement lawsuit between Butamax and Gevo continues in parallel. The ‘376 patent was added to the litigation last September as a counterclaim to Butamax’s original suit against Gevo. Butamax requested that the counterclaims be dismissed since Butamax believes its isobutanol production technology does not fall within the scope of the ‘376 patent claims. A decision on Butamax’s request for preliminary injunction against Gevo is expected in the near term. Trial for this lawsuit is scheduled for April 2013.

The Butamax team began its research on biobutanol in 2004 resulting in key patent filings in 2005. These early priority filings continue to progress through the patent system. As part of an extensive patent portfolio, these Butamax patent applications encompass recombinant microorganisms that produce biobutanol, process engineering for recovering the biobutanol, and methods of making isobutanol.

About Butamax

Butamax™ Advanced Biofuels, LLC, a joint venture between BP and DuPont, was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont’s proven industrial biotechnology experience and BP’s global fuels market knowledge. Butamax’s proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES